We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Tempus AI, Inc.는 미국에서 헬스케어 기술 기업으로 운영됩니다. 회사는 임상의의 데스크톱과 회사의 실험실 진단 기능, 분석 플랫폼, 다중 모달 데이터 저장소 간의 양방향 통합을 지원하는 폐쇄 루프, 풀 스택 Tempus platform을 제공합니다. 또한, 의사 및 기타 의료 서비스 제공자를 위한 임상 애플리케이션인 Hub를 제공하며, Hub는 진단 제품 라인에서 NGS 검사를 위한 엔드투엔드 애플리케이션으로 활용됩니다. 회사는 또한 생명 과학 및 첨단 정밀 연구를 위한 소프트웨어 애플리케이션인 Lens를 제공합니다. NGS 진단, PCR 프로파일링, 기타 해부학적 및 분자 병리 검사 등의 진단 서비스도 제공합니다. 여러 분석법을 통해 대규모 패널 고형암 및 혈액학적 검사를 제공하며, 특히 핵심 임상 분석법인 xT 및 xR은 일반 혈액 또는 타액 분석